By using untargeted metabolomics with UHPLC-HRMS to profile the metabolome of IHH depending on hippurate treatment (500 μM) in insulin resistance conditions (24 h of 100 nM insulin treatment), we were able to discriminate between treatment conditions (Figure 4B, R2Y = 0.821, Q2Y = 0.396, pQ2Y = 0.011). Here, INS is linked to Insulin resistance.